Intensive management of high-utilizing adults with sickle cell disease lowers admissions

American Journal of Hematology

Volumn 90, Issue 3, 2015, Pages 215-219

  Koch, Kathryn L ^a   Karafin, Matthew S ^a,b   Simpson, Pippa ^a,c   Field, Joshua J ^a,b  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b BLOOD RESEARCH INSTITUTE   (United States)

^c Children's Hospital of Wisconsin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN S; HYDROXYUREA; ANALGESIC AGENT; ANTISICKLING AGENT;

ADULT; ADULT DISEASE; ANALGESIA; ARTICLE; AVASCULAR NECROSIS; BLOOD TRANSFUSION; CEREBROVASCULAR ACCIDENT; CHRONIC PAIN; COHORT ANALYSIS; CONTROLLED STUDY; DAY HOSPITAL; DRUG TOLERABILITY; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HOSPITAL READMISSION; HOSPITAL UTILIZATION; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NURSE PRACTITIONER; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SICKLE CELL ANEMIA; ADOLESCENT; ANEMIA, SICKLE CELL; DISEASE MANAGEMENT; EMERGENCY HEALTH SERVICE; HEALTH SERVICE; HOSPITALIZATION; PREVENTION AND CONTROL; STATISTICS AND NUMERICAL DATA; UTILIZATION;

ADOLESCENT; ADULT; ANALGESICS; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD TRANSFUSION; DISEASE MANAGEMENT; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH SERVICES MISUSE; HOSPITALIZATION; HUMANS; HYDROXYUREA; MALE; RETROSPECTIVE STUDIES;

EID: 84923103908     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23912     Document Type: Article

References (19)

1. Brousseau DC, Owens PL, Mosso AL, et al. Acute care utilization and rehospitalizations for sickle cell disease. JAMA 2010;303:1288-1294.
2. Powars DR, Chan LS, Hiti A, et al. Outcome of sickle cell anemia: A 4-decade observational study of 1056 patients. Medicine 2005;84:363-376.
3. Smith WR, Penberthy LT, Bovbjerg VE, et al. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med 2008;148:94-101.
4. Carroll CP, Haywood C Jr, Fagan P, et al. The course and correlates of high hospital utilization in sickle cell disease: Evidence from a large, urban Medicaid managed care organization. Am J Hematol 2009;84:666-670.
5. Lanzkron S, Haywood C Jr, Hassell KL, et al. Provider barriers to hydroxyurea use in adults with sickle cell disease: A survey of the Sickle Cell Disease Adult Provider Network. J Natl Med Assoc 2008;100:968-973.
6. Lanzkron S, Carroll CP, Haywood C Jr. The burden of emergency department use for sickle-cell disease: An analysis of the national emergency department sample database. Am J Hematol 2010;85:797-799.
7. Carroll CP, Haywood C Jr, Lanzkron S. Prediction of onset and course of high hospital utilization in sickle cell disease. J Hosp Med 2011;6:248-255.
8. Weinberger M, Smith DM, Katz BP, et al. The cost-effectiveness of intensive postdischarge care. A randomized trial. Med Care 1988;26:1092-1102.
9. Rich MW, Beckham V, Wittenberg C, et al. A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 1995;333:1190-1195.
10. Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: An approach for the management of uncomplicated painful crises. Blood 2000;95:1130-1136.
11. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood 2004;103:4023-4027.
12. Quinn CT, Rogers ZR, McCavit TL, et al. Improved survival of children and adolescents with sickle cell disease. Blood 2010;115:3447-3452.
13. Wright J, Bareford D, Wright C, et al. Day case management of sickle pain: 3 years experience in a UK sickle cell unit. Br J Haematol 2004;126:878-880.
14. Raphael JL, Oyeku SO. Sickle cell disease pain management and the medical home. Hematology Am Soc Hematol Educ Program 2013;2013:433-438.
15. Vichinsky EP. Comprehensive care in sickle cell disease: Its impact on morbidity and mortality. Semin Hematol 1991;28:220-226.
16. Artz N, Whelan C, Feehan S. Caring for the adult with sickle cell disease: Results of a multidisciplinary pilot program. J Natl Med Assoc 2010;102:1009-1016.
17. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. JAMA 2003;289:1645-1651.
18. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol 2010;85:403-408.
19. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr 2001;139:785-789.